Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With CF-LVAD
| Status: | Recruiting |
|---|---|
| Conditions: | Cardiology, Gastrointestinal |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Gastroenterology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/31/2019 |
| Start Date: | January 23, 2019 |
| End Date: | January 1, 2021 |
| Contact: | Nir Uriel, MD |
| Email: | nuriel@medicine.bsd.uchicago.edu |
| Phone: | 7737029396 |
Open-Label Prospective Randomized Control Trial to Investigate the Efficacy of Omega-3 Fatty Acid Therapy in Preventing Gastrointestinal Bleeding in Patients With Continuous-Flow Left Ventricular Assist Device
This study evaluates the efficacy of high-dose fish oil in decreasing rates of
gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices.
Half of the patients without history of bleeding will receive fish oil while the other half
will not. Half of the patients with history of bleeding will receive fish oil while the other
half will not. Markers of angiogenesis and inflammation, as well as changes in the microbiome
will be assessed in each group.
gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices.
Half of the patients without history of bleeding will receive fish oil while the other half
will not. Half of the patients with history of bleeding will receive fish oil while the other
half will not. Markers of angiogenesis and inflammation, as well as changes in the microbiome
will be assessed in each group.
A potential mechanism of bleeding in patients with continuous-flow left ventricular assist
devices (CF-LVAD) is dysfunctional angiogenesis. Angiogenesis is a complicated process
controlled by several markers. Previous studies have shown that elevated Angiopoietin-2 and
TNF-alpha are associated with bleeding events in CF-LVAD patients.
Fish oil has anti-inflammatory and potentially anti-angiogenic properties. A retrospective
study of CF-LVAD patients on high-dose fish oil showed a marked decrease in gastrointestinal
bleeding rates in these patients. Additionally, these patients had lower levels of
circulating Angiopoietin-2. Fish oil is known to have an effect on the microbiome, and the
aforementioned effects may be seen in changes of the microbiota.
devices (CF-LVAD) is dysfunctional angiogenesis. Angiogenesis is a complicated process
controlled by several markers. Previous studies have shown that elevated Angiopoietin-2 and
TNF-alpha are associated with bleeding events in CF-LVAD patients.
Fish oil has anti-inflammatory and potentially anti-angiogenic properties. A retrospective
study of CF-LVAD patients on high-dose fish oil showed a marked decrease in gastrointestinal
bleeding rates in these patients. Additionally, these patients had lower levels of
circulating Angiopoietin-2. Fish oil is known to have an effect on the microbiome, and the
aforementioned effects may be seen in changes of the microbiota.
Inclusion Criteria:
1. Subject has signed consent
2. Age > 18 years
3. Subjects with a CF-LVAD or are scheduled to receive a CF-LVAD implant
Exclusion Criteria:
1. Psychiatric disorder or disease, irreversible cognitive dysfunction or psychosocial
issues that might impair compliance with the study.
2. Patients already taking fish oil.
We found this trial at
1
site
Click here to add this to my saved trials
